NEW YORK (GenomeWeb) ­– The Atlantic Cancer Research Institute has agreed to license extracellular vesicle (EV) isolation technology to BioVendor – Laboratorní Medicína, a Czech biotechnology company developing in vitro diagnostics and research-use-only immunoassays.

The agreement gives BioVendor non-exclusive rights to use ACRI's Vn96 synthetic peptide for isolation of EVs to diagnose disease via liquid biopsy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.